blood, but their numbers can be dramatically, albeit transiently, increased following treatment with conventional chemotherapy and administration of haemopoietic growth An essential prerequisite for successful procurement of sufficient autologous peripheral blood progenitor cells factors such as granulocyte colony-stimulating factor (G-CSF). 4, 5 After mobilisation the PBPC are removed from the (PBPC) for engraftment is the optimal timing of collection. A number of surrogate markers of peripheral patient's circulation by apheresis and the adequacy of the collection is assessed by the product's content of nucleated blood progenitor cells were analysed to identify a single test which could predict the optimum time to harvest, cells, mononuclear cells, granulocyte-macrophage colonyforming units (CFU-GM) or CD34 + cells. providing at least 2 × 10 6 CD34 + cells/kg patient body weight. The study comprised 95 patients undergoing
؉ cell and CFU-GM yield of the corresponding apheresis efficiency. This study involved the analysis of the WCC, monoproduct. Provided the mobilisation sample contained у20 × 10 6 CD34 ؉ cells/ml, 94% of single collections, nuclear cell count (MNC), CD34 + cells and colony-forming units (CFU) on samples obtained from 95 patients with both performed the following day, contained у2 × 10 6
CD34
+ cells/kg. haematological and nonhaematological diseases. The PBPC mobilisation was carried out using a variety of different Keywords: peripheral blood progenitor cells; leucapheresis; CD34 ϩ cells; white cell count regimens. The results from 157 PBPC harvests, mobilisation and pre-harvest samples were analysed retrospectively, with the aim of identifying a single test which could predict the optimum time to harvest in order to collect at Haemopoietic progenitor cells obtained from peripheral least 2 × 10 6 CD34 + cell/kg patient body weight, the thresblood are increasingly being used as an alternative to autohold value required by our referring hospitals. This report logous bone marrow transplantation for haemopoietic supconfirms and extends our previously reported data on 39 port after intensive myeloablative chemotherapy in patients patients, all from the same referring hospital. 6 with haematological diseases and with solid tumours. 17-64 years) and their median weight 71 kg (range 46-150 kg). Fifty-three patients had haematological maligsubsequent washing steps with phosphate-buffered saline/bovine serum albumin solution (PBS/BSA), the nancies and 42 had solid tumours. Breast cancer patients (n = 22) always commenced apheresis on day 11 (day of samples were analysed on the flow cytometer using the LYSIS II software (Becton Dickinson). All tests were set chemotherapy is day 1). For the other groups of patients, lymphoma (n = 23), myeloma (n = 21), germ cell tumour up in duplicate, and a total of 50 000 to 60 000 events were acquired for each test. (n = 20) and leukaemia (n = 9), harvesting started when the WCC rose above 1 × 10 6 /ml, but after about 6 months A forward scatter vs fluorescence-1 (FSC v FL1) dot plot was used to discriminate the CD45 + FITC-labelled leucopatients were harvested when the peripheral blood CD34 count was at least 8 × 10 3 cells/ml. cyte population from nonlysed erythrocytes, platelets and cell debris. Clonogenic assays insufficient, the leucapheresis procedure was repeated on the following day, and where necessary, on successive These assays were performed only on the samples taken from the leucapheresis collections. Granulocyte-macrodays. One hundred and fifty-seven PBPC leucapheresis procedures were performed, with an average of 1.7 collections phage (CFU-GM), erythroid (BFU-E) and multipotential (CFU-GEMM) colony-forming cells were assayed using a per patient (range 1-4).
modification of a technique previously described. 8 Briefly, the mononuclear cells were suspended in a culSamples ture medium consisting of Iscove's modified Dulbecco's medium (Life Technologies, Glasgow, UK), 1.3% methylSamples were taken during the patient's mobilisation regimen, into potassium EDTA, and referred to as mobilisation cellulose (Sigma-Aldrich, Poole, UK), 30% fetal bovine serum (Stem Cell Technologies: Metachem Diagnostics, samples. Peripheral blood (PB) samples were also taken immediately prior to the leucapheresis procedure and were Northampton, UK), 10% bovine serum albumin (Stem Cell Technologies), 2 mm l-glutamine (Life Technologies, designated as pre-harvest samples. Once the procedure was completed a sample was removed from the leucapheresis 10 −4 m 2-mercaptoethanol (Sigma-Aldrich), 3 U/ml erythropoietin (Stem Cell Technologies) and supernatant from the collection for analysis (harvest sample).
All samples were stored at ambient temperature and human bladder carcinoma cell line 5637 (CM5637) as the source of growth factors. The cells were plated in triplicate, tested as soon as possible. In all cases this was within 24 h of collection.
at concentrations of 0.25 and 0.5 × 10 5 cells/ml, in 24-well tissue culture plates (Falcon; Marathon Laboratories, London, UK) and incubated at 37°C in a humidified atmosphere Full blood count and differential consisting of 5% CO 2 in air. CFU-GM, BFU-E and mixed cell colonies were identified and counted by microscopic All samples were assessed for their leucocyte, erythrocyte, platelet and differential leucocyte counts using an autoexamination at day 14. mated haematology analyser Technicon H1 or H3 (Bayer, Newbury, UK). The percentage of mononuclear cells was Statistical analysis determined as the sum of the lymphocytes, monocytes and large undifferentiated cells.
The results were entered onto an Excel database and analysed for statistical correlation. The correlation tool determines whether two data sets move together independent of CD34 positive cell enumeration the units of measurement; whether large values of one set are associated with large values of the other (positive CD34
+ cell analysis of all the samples was performed using a dual labelling flow cytometric technique 7 on a FACSort correlation), whether small values of one set are associated with large values of the other (negative correlation); or flow cytometer (Becton Dickinson, Oxford, UK). This technique was carried out using whole blood from the mobiliswhether the values in the two sets are unrelated (correlation tends towards zero). Correlations with the number of ation and pre-harvest samples, or samples taken directly from the mononuclear cell leucapheresis collections. CD34 + cells collected in a single leucapheresis harvest were looked for. 1 × 10 6 white blood cells (WBC) were simultaneously labelled, for 30 min at room temperature, with a FITC-conjugated anti-C45 (anti-HLe-1; Becton Dickinson) and a PEconjugated anti-CD34 (anti-HPCA-2; Becton Dickinson); Results corresponding isotype controls were included to establish the background nonspecific staining.
Of the 95 patients tested, four failed to mobilise, as indicated by no detectable or very low circulating CD34 numAfter labelling, lysing of the red cells was performed using FACS lysing solution (Becton Dickinson). After bers, and therefore no PBPC were harvested. In 42 cases a 3) the pre-harvest samples were assessed for circulating were collected per harvest. In patients with myeloma CD34 + cells (n = 92), the values obtained gave a very good (n = 20), the harvested cells were to be positively selected prediction of the CD34 content of the PBPC harvest, as for CD34 and the protocol followed required a minium of indicated by a correlation coefficient of r = 0.95 (Table 1) . two leucapheresis collections.
Eighty-four apheresis collections were analysed for both The CD34 content of the harvest (as expressed per kg their CFU and their CD34 + cell content. Good correlation, of patient's body weight) was independent of the WCC of r = 0.82, was obtained between the CD34 + cell numbers and the PB mobilisation samples collected on the day preceding the CFU-GM numbers of the leucapheresis harvests. Also, the leucapheresis procedure, as shown in Figure 1 . Furtherthe circulating CD34 + cells in both the mobilisation and more, the correlation coefficient between the WCC or the pre-harvest samples gave a good prediction of the CFU-MNC of the mobilisation samples and the number of GM content of the collection, with correlation coefficients CD34 + cells in a single leucapheresis product (n = 102) was of r = 0.80 and r = 0.72, respectively. Again in this case it r = 0.13 and r = 0.12, respectively. The results suggest that was the sample collected on the day preceding the leucaboth the WCC and MNC are nonpredictive of the final pheresis procedure that gave the better predictive value. CD34
+ cell content of the harvest (Table 1) . The percentage of single leucapheresis collections able The WCC and MNC of the pre-harvest PB samples to achieve the target CD34 + cell yield, as predicted by the (n = 92) taken immediately prior to the leucapheresis proabsolute numbers of circulating CD34 + cells in the PB, of cedure, showed only weak correlation with the number of both mobilisation and pre-harvest samples, are listed in CD34 cells collected in the harvest, as reflected by the cor- Table 2 . To obtain over 2 × 10 6 CD34 + cells per kg patient relation coefficient of r = 0.30 and r = 0.40, respectively body weight (range 2.1-29.3 × 10 6 CD34/kg) from a single ( Table 1 ). The higher correlation value obtained with the MNC is not unexpected, since the CD34 + cells are contained within the mononuclear cell compartment. leucapheresis product in at least 94% of patients, a mobilismobilisation period, generally starting at about day 9 or 10, the day to perform the leucapheresis can be planned. Once ation sample with у20 × 10 3 /ml CD34 + cells or a pre-harvest sample with у30 × 10 3 /ml CD34 + cells is necessary a level of at least 20 × 10 3 CD34 + cells/ml was achieved, by performing leucapheresis on the following day at least (Table 2) . By waiting until the circulating CD34 numbers achieved levels in excess of 20 × 10 3 /ml, resulted in only 2 × 10 6 CD34 + cells/kg were collected in a single harvest in 94% of the procedures. Harvesting the PBPC before this a very limited improvement in the number of collections expected to reach the required target value in a single collevel is reached gives very poor collections. Similarly other target collections can be predicted. Measuring the CD34 lection. These target circulating CD34 counts can be recalculated for whatever number of CD34 + cells are required count on the day proceding the leucapheresis procedure allows for more efficient organisation, minimising the probin the leucapheresis product.
Transplantation data on 45 of these patients indicates that lems of the patient and of the leucapheresis staff. Similar results have been reported by Schots et al 13 but with fewer adequate numbers of stem cells and progenitor cells were harvested as reflected by the days to neutrophil and platelet patients and no indication of attempts to limit the number of leukapheresis procedures performed. Haas et al 14 also engraftment. Neutrophil recovery to Ͻ0.5 × 10 9 /l occurred at a median day of 12 (range 6-18) and platelet recovery demonstrated a clear correlation between circulating CD34 cells and their numbers in the resulting harvest, but in a to Ͼ50 × 10 9 /l at a median day of 16 (range 5-41). population that consisted entirely of lymphoma patients. Flow cytometric analysis of CD34 + cells is a reliable and rapid method for measuring progenitor cells, and the results Discussion closely relate to progenitor cell clonogenic assays. CD34 enumeration can be performed within 2 h from receipt of The use of autologous PBPC, as an alternative to autologous bone marrow, to provide haemopoietic support followthe sample, allowing decisions to be made rapidly on the time to collect adequate PBPC and also whether a subing high-dose therapy, has escalated in the past 5 years. The current threshold value of CD34
+ cells recommended sequent leucapheresis is necessary. It is important to remember that CD34 enumeration is not a standardised test to induce rapid and successful engraftment or haemopoietic recovery is at least 2 × 10 6 CD34 + cells per kilogram patient between laboratories, therefore other centres would need to evaluate their own peripheral blood CD34 level that prebody weight, 9 ,10 although in the literature other target doses are quoted.
11 A simple parameter to predict the optimal dicts when to perform the leucapheresis. Although colonyforming cell numbers correlate well with the CD34 + cell time to harvest the optimal number of progenitor cells is still an issue. The aim of this study was to find a numbers, the colony-forming assay requires 14 days incubation, and is thefefore, obviously not a viable technique parameter(s), which, independent of both the diagnosis of the patients and the mobilisation regimens used, could to predict when to harvest progenitor cells.
In conclusion, monitoring circulating CD34 + cells in perallow this prediction.
The criteria for harvesting changed during the study, ipheral blood samples during a patient's mobilisation regimen is a very useful predictor of when to collect PBPC to initially all patients were apheresed when their WCC was greater than 1 × 10 6 /ml. However, after 6 months when it provide an adequate harvest for successful engraftment. These results indicate that the optimal time for collecting became apparent that the CD34 counts gave a better indication of the quality of the apheresis product, a value of PBPC, using the described protocol, is when a peripheral blood sample contains at least 20 × 10 3 circulating CD34 + 8 × 10 3 CD34 + cells/ml was used as an indication to harvest, except in the case of breast cancer patients who were cells/ml. This value provided at least 2 × 10 6 CD34 + cells/kg in a single leucapheresis, harvested the following always leukapheresed on day 11. CD34 counts were started at day 9 and 10 when the WCC started to rise, and an day, in 94% of the collections regardless of the patient's diagnosis or mobilisation regimen. average of two counts (range 1-7) were performed for each patient.
The peripheral WCC has previously been used as an indicator of the optimum day for harvesting. 10, 12 The dataof the WCC, providing no reliable prediction for the number of CD34 + cells collected in the PBPC harvest. 
